secwatch.observer — SEC 8-K summary
======================================

Issuer:     vTv Therapeutics Inc. (VTVT)
CIK:        0001641489
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001641489-24-000073
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

vTv Therapeutics Q3 net loss narrows to $4.8M; FDA clinical hold on cadisegliatin continues
--------------------------------------------------------------------------------

- Net loss of $4.8M ($0.88/share) vs $6.7M ($3.19) in Q3 2023; nine-month net loss $14.8M.
- Cash $41.6M at Sep 30, 2024, up from $9.4M at Dec 31, 2023, boosted by private placement and ATM.
- R&D spend $3.2M (up from $2.8M) on higher indirect costs; G&A $3.3M (up from $2.5M) due to share-based and legal.
- Cadisegliatin program under FDA clinical hold since July 2024; company addressing basis for hold.
- No revenue in Q3 2024; YTD revenue $1.0M from prior periods.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641489/000164148924000073/0001641489-24-000073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641489/000164148924000073/vtvt-20241112.htm
  HTML page:      https://secwatch.observer/filing/0001641489-24-000073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer